Everolimus Modulation of Anti-tumor T CD4 Immune Responses

Inclusion Criteria: * Performance status ECOG-WHO 0, 1 or 2 * Metastatic renal cancer * Patient candidate to everolimus treatment * signed written informed consent * fertile women with adequate contraception during the study and until 8 weeks after stopping treatment Exclusion Criteria: * Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) * History of immune deficiency * Hypersensitivity against rapamycin and derived * Prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intra-epithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years * Active autoimmune diseases, HIV, hepatitis C or B virus * Patients with any medical or psychiatric condition or disease, * Patients under guardianship, curatorship or under the protection of justice.